JP2013523867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523867A5 JP2013523867A5 JP2013504265A JP2013504265A JP2013523867A5 JP 2013523867 A5 JP2013523867 A5 JP 2013523867A5 JP 2013504265 A JP2013504265 A JP 2013504265A JP 2013504265 A JP2013504265 A JP 2013504265A JP 2013523867 A5 JP2013523867 A5 JP 2013523867A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- substituted
- acceptable salt
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- -1 2-methoxy-2-propyl Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003235 pyrrolidines Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 210000000244 kidney pelvis Anatomy 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229960000575 trastuzumab Drugs 0.000 claims 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000000621 bronchi Anatomy 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 210000000867 larynx Anatomy 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- GXHAENUAJYZNOA-UHFFFAOYSA-N oxolane-2-carboxamide Chemical compound NC(=O)C1CCCO1 GXHAENUAJYZNOA-UHFFFAOYSA-N 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229950006410 tezacitabine Drugs 0.000 claims 2
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- DPWFPLHTMSSYKU-GOMRNUEMSA-N (2s)-n-[(1r)-1-[2-benzyl-5-(2,5-difluorophenyl)-1,2,4-triazol-3-yl]-2,2-dimethylpropyl]-n-[[(3r,4r)-4-fluoropyrrolidin-3-yl]methyl]-2-hydroxypropanamide Chemical compound C[C@H](O)C(=O)N([C@@H](C=1N(N=C(N=1)C=1C(=CC=C(F)C=1)F)CC=1C=CC=CC=1)C(C)(C)C)C[C@H]1CNC[C@@H]1F DPWFPLHTMSSYKU-GOMRNUEMSA-N 0.000 claims 1
- OSIGMKFSZPQTOV-PXAYELCQSA-N (2s)-n-[(1r)-1-[5-(2,5-difluorophenyl)-2-[(3-fluorophenyl)methyl]-1,2,4-triazol-3-yl]-2,2-dimethylpropyl]-n-[[(3r,4r)-4-fluoropyrrolidin-3-yl]methyl]-2-hydroxypropanamide Chemical compound C[C@H](O)C(=O)N([C@@H](C=1N(N=C(N=1)C=1C(=CC=C(F)C=1)F)CC=1C=C(F)C=CC=1)C(C)(C)C)C[C@H]1CNC[C@@H]1F OSIGMKFSZPQTOV-PXAYELCQSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 239000012025 fluorinating agent Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- AWBVBYIKAUDSGH-ZDVAVYJTSA-N n-[(1r)-1-[2-benzyl-5-(2,5-difluorophenyl)-1,2,4-triazol-3-yl]-2,2-dimethylpropyl]-n-[[(3r,4r)-4-fluoropyrrolidin-3-yl]methyl]-2,6-dimethylmorpholine-4-carboxamide Chemical compound C1C(C)OC(C)CN1C(=O)N([C@@H](C=1N(N=C(N=1)C=1C(=CC=C(F)C=1)F)CC=1C=CC=CC=1)C(C)(C)C)C[C@@H]1[C@@H](F)CNC1 AWBVBYIKAUDSGH-ZDVAVYJTSA-N 0.000 claims 1
- NIGJERGZJNCPOP-VBCPYKANSA-N n-[(1r)-1-[5-(2,5-difluorophenyl)-2-[(3-fluorophenyl)methyl]-1,2,4-triazol-3-yl]-2,2-dimethylpropyl]-n-[[(3r,4r)-4-fluoropyrrolidin-3-yl]methyl]-2,6-dimethylmorpholine-4-carboxamide Chemical compound C1C(C)OC(C)CN1C(=O)N([C@@H](C=1N(N=C(N=1)C=1C(=CC=C(F)C=1)F)CC=1C=C(F)C=CC=1)C(C)(C)C)C[C@@H]1[C@@H](F)CNC1 NIGJERGZJNCPOP-VBCPYKANSA-N 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- 238000010653 organometallic reaction Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 238000007142 ring opening reaction Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000037396 body weight Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- LOBCDGHHHHGHFA-LBPRGKRZSA-N (S)-monastrol Chemical compound CCOC(=O)C1=C(C)NC(=S)N[C@H]1C1=CC=CC(O)=C1 LOBCDGHHHHGHFA-LBPRGKRZSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- YSNVKDGEALPJGC-UHFFFAOYSA-N Cc(cc(cc1)F)c1F Chemical compound Cc(cc(cc1)F)c1F YSNVKDGEALPJGC-UHFFFAOYSA-N 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32465110P | 2010-04-15 | 2010-04-15 | |
| US61/324,651 | 2010-04-15 | ||
| PCT/EP2011/055840 WO2011128381A1 (en) | 2010-04-15 | 2011-04-13 | Triazole compounds as ksp inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523867A JP2013523867A (ja) | 2013-06-17 |
| JP2013523867A5 true JP2013523867A5 (enExample) | 2014-04-24 |
Family
ID=44009916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013504265A Pending JP2013523867A (ja) | 2010-04-15 | 2011-04-13 | Ｋｓｐ阻害剤としてのトリアゾール化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8546434B2 (enExample) |
| EP (1) | EP2558450A1 (enExample) |
| JP (1) | JP2013523867A (enExample) |
| KR (1) | KR20130100056A (enExample) |
| CN (1) | CN102844307A (enExample) |
| AR (1) | AR080893A1 (enExample) |
| AU (1) | AU2011239977B2 (enExample) |
| BR (1) | BR112012025879A2 (enExample) |
| CA (1) | CA2794406A1 (enExample) |
| EA (1) | EA201201404A1 (enExample) |
| MX (1) | MX2012011910A (enExample) |
| TW (1) | TW201136925A (enExample) |
| UY (1) | UY33332A (enExample) |
| WO (1) | WO2011128381A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8748626B2 (en) * | 2010-04-15 | 2014-06-10 | Novartis Ag | Oxazole and thiazole compounds as KSP inhibitors |
| US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| WO2014151030A1 (en) * | 2013-03-15 | 2014-09-25 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| MXPA05003830A (es) | 2002-10-11 | 2005-06-23 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
| WO2005113507A1 (en) * | 2004-05-21 | 2005-12-01 | Novartis Vaccines And Diagnostics Inc. | Substituted quinoline derivatives as mitotic kinesin inhibitors |
| US7576221B2 (en) * | 2004-06-18 | 2009-08-18 | Novartis Vaccines And Diagnostics, Inc. | Substituted imidazole derivatives |
| CA2584979A1 (en) | 2004-10-19 | 2006-05-11 | Novartis Vaccines And Diagnostics, Inc. | Indole and benzimidazole derivatives |
| AU2006206738A1 (en) * | 2005-01-19 | 2006-07-27 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| EP1868601A4 (en) * | 2005-04-07 | 2008-12-10 | Merck & Co Inc | MITOTIC KINESINE HEMMER |
| TW200800951A (en) | 2005-08-09 | 2008-01-01 | Novartis Ag | Substituted imidazole compounds as KSP inhibitors |
| US7325386B2 (en) | 2005-10-17 | 2008-02-05 | Etienne Kissling | Double action vertical form-fill-seal apparatus |
| US7902240B2 (en) * | 2006-11-13 | 2011-03-08 | Novartis Ag | Substituted pyrazole and triazole compounds as KSP inhibitors |
| EP2106399A2 (en) | 2007-01-05 | 2009-10-07 | Novartis AG | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) |
| US8748626B2 (en) | 2010-04-15 | 2014-06-10 | Novartis Ag | Oxazole and thiazole compounds as KSP inhibitors |
-
2011
- 2011-04-13 KR KR1020127029781A patent/KR20130100056A/ko not_active Withdrawn
- 2011-04-13 MX MX2012011910A patent/MX2012011910A/es not_active Application Discontinuation
- 2011-04-13 EA EA201201404A patent/EA201201404A1/ru unknown
- 2011-04-13 US US13/085,746 patent/US8546434B2/en not_active Expired - Fee Related
- 2011-04-13 AR ARP110101254A patent/AR080893A1/es unknown
- 2011-04-13 BR BR112012025879A patent/BR112012025879A2/pt not_active IP Right Cessation
- 2011-04-13 CA CA2794406A patent/CA2794406A1/en not_active Abandoned
- 2011-04-13 CN CN2011800184156A patent/CN102844307A/zh active Pending
- 2011-04-13 WO PCT/EP2011/055840 patent/WO2011128381A1/en not_active Ceased
- 2011-04-13 EP EP11715682A patent/EP2558450A1/en active Pending
- 2011-04-13 JP JP2013504265A patent/JP2013523867A/ja active Pending
- 2011-04-13 AU AU2011239977A patent/AU2011239977B2/en not_active Expired - Fee Related
- 2011-04-14 TW TW100113030A patent/TW201136925A/zh unknown
- 2011-04-14 UY UY0001033332A patent/UY33332A/es not_active Application Discontinuation
-
2013
- 2013-08-28 US US14/012,167 patent/US20140056880A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4161511A1 (en) | Novel small molecules for targeted degradation of untargetable kras in cancer therapy | |
| JP2008528671A5 (enExample) | ||
| WO2016164401A1 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| WO2020232119A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| BR112019021393A2 (pt) | imunoterapia combinada contra o câncer com o complexo de anel macrocíclico penta-aza | |
| WO2018122168A1 (en) | Combinations of bub1 kinase and parp inhibitors | |
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2013523867A5 (enExample) | ||
| TW200512198A (en) | 5-arylpyrimidines as anticancer agents | |
| CN101484443B (zh) | 放射线治疗增强剂 | |
| JP6063472B2 (ja) | 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 | |
| TWI557128B (zh) | 組成物在製備用於預防或治療非小細胞肺癌之藥物之用途 | |
| JP2013525290A5 (enExample) | ||
| WO2015182628A1 (ja) | ピラジンカルボキサミド化合物を有効成分とする医薬組成物 | |
| JP2011514356A5 (enExample) | ||
| JP2010500971A5 (enExample) | ||
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 | |
| US12303508B2 (en) | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | |
| US20190167608A1 (en) | Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents | |
| MXPA06002939A (es) | 6-aril-7-haloimidazo[1,2-a]pirimidinas como agentes contra el cancer. | |
| Vasiliou et al. | SNS-032 | |
| JP2023554532A (ja) | 医薬組成物の肺癌治療における使用 | |
| JP2007530567A (ja) | エポチロン及びカルボプラチンを用いる併用療法 | |
| TWI307628B (en) | Use of zd0473 in combination with a non-platinum based anti-cancer agent | |
| JP2020063209A (ja) | 細胞周期停止剤および抗腫瘍剤 |